| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 398 | 2019 |
| Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE … S Walmsley, A Baumgarten, J Berenguer, F Felizarta, E Florence, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 70 (5), 515-519, 2015 | 284 | 2015 |
| Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of … J Van Wyk, F Ajana, F Bisshop, S De Wit, O Osiyemi, J Portilla Sogorb, ... Clinical Infectious Diseases 71 (8), 1920-1929, 2020 | 251 | 2020 |
| Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos (t) ide reverse … JR Arribas, PM Girard, R Landman, J Pich, J Mallolas, ... The Lancet Infectious Diseases 15 (7), 785-792, 2015 | 194 | 2015 |
| Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV F Pulido, JR Arribas, R Delgado, E Cabrero, J González-García, ... Aids 22 (2), F1-F9, 2008 | 194 | 2008 |
| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 5 (5), e211-e220, 2018 | 162 | 2018 |
| Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis JR Arribas, R Delgado, A Arranz, R Muñoz, J Portilla, J Pasquau, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 51 (2), 147-152, 2009 | 145 | 2009 |
| Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated … C Orrell, DP Hagins, E Belonosova, N Porteiro, S Walmsley, V Falcó, ... The Lancet HIV 4 (12), e536-e546, 2017 | 136 | 2017 |
| Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat … C Orkin, JM Molina, E Negredo, JR Arribas, J Gathe, JJ Eron, ... The Lancet HIV 5 (1), e23-e34, 2018 | 128 | 2018 |
| Dyslipidemia related to antiretroviral therapy. V Estrada, J Portilla AIDS reviews 13 (1), 49-56, 2011 | 124 | 2011 |
| Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain N Merchante, E Merino, J López-Aldeguer, F Jover, ... Clinical Infectious Diseases 56 (1), 143-150, 2013 | 95 | 2013 |
| Low-level HIV viremia is associated with microbial translocation and inflammation S Reus, J Portilla, J Sánchez-Payá, L Giner, R Francés, J Such, V Boix, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 62 (2), 129-134, 2013 | 90 | 2013 |
| Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression F Pulido, I Pérez-Valero, R Delgado, A Arranz, J Pasquau, J Portilla, ... Antiviral therapy 14 (2), 195-201, 2009 | 83 | 2009 |
| Functional status determined by Barthel Index predicts community acquired pneumonia mortality in general population J Murcia, P Llorens, J Sánchez-Payá, S Reus, V Boix, E Merino, ... Journal of Infection 61 (6), 458-464, 2010 | 69 | 2010 |
| Efficacy and safety of switching to dolutegravir/lamivudine versus continuing a tenofovir alafenamide–based 3-or 4-drug regimen for maintenance of virologic suppression in … O Osiyemi, S De Wit, F Ajana, F Bisshop, J Portilla, JP Routy, C Wyen, ... Clinical Infectious Diseases 75 (6), 975-986, 2022 | 66 | 2022 |
| Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 … JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ... The lancet HIV 7 (1), e16-e26, 2020 | 62 | 2020 |
| Anal human papillomavirus genotype distribution in HIV-infected men who have sex with men by geographical origin, age, and cytological status in a Spanish cohort M Torres, C González, J del Romero, P Viciana, A Ocampo, ... Journal of Clinical Microbiology 51 (11), 3512-3520, 2013 | 62 | 2013 |
| Human immunodeficiency virus/hepatitis C virus coinfection in Spain: prevalence and patient characteristics J Berenguer, A Rivero, I Jarrín, MJ Núñez, MJ Vivancos, M Crespo, ... Open forum infectious diseases 3 (2), ofw059, 2016 | 60 | 2016 |
| Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions M Paz-Zulueta, L Álvarez-Paredes, JC Rodríguez Díaz, P Parás-Bravo, ... BMC cancer 18, 1-9, 2018 | 58 | 2018 |
| Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy J Berenguer, B Alejos, V Hernando, P Viciana, M Salavert, I Santos, ... Aids 26 (17), 2241-2246, 2012 | 57 | 2012 |
